Metastatic Pancreatic Cancer x Dr. Michael Pishvaian 2026 UPDATE Part 2

In this second part of their 2026 update on metastatic pancreatic cancer, Dr. Michael Pishvain joins Two Onc Docs to provide a comprehensive overview of current and emerging treatment strategies. The discussion begins with frontline systemic therapies, highlighting the evolution from outdated gemcitabine to modern triplet regimens like Folfirinox, Nab-paclitaxel/gemcitabine, and the newer Nalirifox. Dr. Pishvain emphasizes that while all three regimens improve response rates and quality of life, treatment selection depends on patient performance status, tolerance, and preferences. He advocates strongly for maintenance therapy—particularly oral capecitabine after Folfirinox—as a way to sustain disease control and quality of life without compromising survival. A key focus is the role of biomarker-driven therapies, especially in patients with germline or somatic BRCA1/2 or PALB2 mutations, where maintenance olaparib has proven benefit in the POLO trial. The episode then delves into the revolutionary impact of KRAS-targeted therapies, starting with G12C inhibitors like adagrasib and sotorasib, which show impressive response rates in the rare 1% of patients with this mutation. The future lies in pan-RAS inhibitors like darovasib and allele-specific inhibitors (e.g., G12D inhibitors), which are showing remarkable efficacy in broader RAS-mutant populations. Dr. Pishvain also covers rare but actionable alterations such as NTRK, NRG1, RET, BRAF, FGFR fusions, MSI-high status, and HER2 positivity—each with targeted options, though access and efficacy remain challenges. The episode concludes with a strong call for universal molecular testing, including RNA fusion detection, to ensure no patient misses out on precision therapy. The final episode in the series will cover supportive care and upcoming clinical trials. Key takeaways include: 1) Maintenance therapy with capecitabine after Folfirinox significantly improves quality of life without harming survival; 2) All metastatic pancreatic cancer patients should undergo comprehensive molecular testing to identify rare but treatable targets; 3) KRAS G12C and G12D inhibitors are game-changers for their respective subgroups; 4) Pan-RAS inhibitors like darovasib represent a potential paradigm shift in treating the vast majority of RAS-mutant pancreatic cancers; 5) Treatment selection should be individualized based on performance status, side effect profiles, and patient preferences; 6) The era of precision oncology in pancreatic cancer is now, and testing is non-negotiable; 7) Future trials are exploring RAS inhibitors as maintenance therapy, potentially extending disease control; 8) Despite challenges, the field is advancing rapidly, offering renewed hope for patients.